NCT06567782 2026-03-12
AZUR-4
GlaxoSmithKline
Phase 2 Recruiting
Clinical Trials
11 trialsNCT06405230 2026-02-03
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
GlaxoSmithKline
Phase 1/2 Recruiting
NCT05855200 2026-01-23
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
GlaxoSmithKline
Phase 3 Recruiting
NCT04544995 2026-01-21
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)
GlaxoSmithKline
Phase 1 Terminated
NCT06879717 2026-01-16
PULMO-01
iOnctura
Phase 1/2 Active not recruiting
NCT06062420 2026-01-09
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
GlaxoSmithKline
Phase 2 Active not recruiting
NCT03843359 2026-01-08
A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Active not recruiting
NCT05565378 2026-01-08
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
GlaxoSmithKline
Phase 2 Active not recruiting
NCT05723562 2026-01-08
AZUR-1
GlaxoSmithKline
Phase 2 Active not recruiting
NCT03602859 2025-12-31
FIRST
Tesaro, Inc.
Phase 3 Active not recruiting
NCT07108270 2025-12-22
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
GlaxoSmithKline
Phase 2 Recruiting